Trials / Not Yet Recruiting
Not Yet RecruitingNCT07487766
The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis
A Phase 1/2, Single-Blinded Trial to Evaluate the Safety and Efficacy of Intra-Articular (IA) Injection of XytriX in Adult Subjects With Grade I-IV Knee Osteoarthritis (KOA)
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- TricelX Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to study the safety and efficacy of XytriX, an umbilical cord-derived stem cell product, in the treatment of Grade I-IV knee osteoarthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mesenchymal Stem Cell Injection | Subjects will receive an intra-articular injection of mesenchymal stem cells derived from umbilical cord tissue |
Timeline
- Start date
- 2026-05-01
- Primary completion
- 2027-05-01
- Completion
- 2028-12-01
- First posted
- 2026-03-23
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07487766. Inclusion in this directory is not an endorsement.